HistoSonics
HI
HistoSonics develops the Edison histotripsy system, a non-invasive therapeutic ultrasound platform. It focuses sound energy to create controlled cavitation that breaks down targeted tissue without incisions. The technology is used for image-guided treatment of solid lesions, including liver tumors, and is intended for interventional radiology and surgical care settings.
Founded by Thomas Davison (Co-Founder), M. Christine Gibbons (Co-Founder), Jim Bertolina (Co-Founder)
Blended valuation$3.7B
Valuation history
Weekly blended valuation with priced funding rounds marked on the timeline.
$3.8B
blended valuation
Oct 20, 2025$2.1BOct 5, 2026
All rounds
4 funding rounds, newest first.
| Round | Announced | Raised | Post-money |
|---|---|---|---|
| Round | Jun 22, 2026 | — | $3.8B |
| Round | Oct 20, 2025 | — | $2.3B |
| Round | Oct 16, 2025 | $250M | — |
| Series D | Aug 15, 2024 | $102M | — |
Investors
8 investors across all rounds.
- BEBezos Expeditions
- FFFounders Fund
- JBJeff Bezos
- KGK5 Global
- PTPeter Thiel
- WMWellington Management
- TBThiel Bio Fund
- YOYosemite
Invest in the private markets on Legion
Registered users see full trading activity, every investor, rankings, and live deals.
Data as of Oct 14, 2026. Valuations are estimates blended from primary and secondary-market signals — not investment advice.